From the Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI.
Female Pelvic Med Reconstr Surg. 2021 Feb 1;27(2):e481-e483. doi: 10.1097/SPV.0000000000000967.
The aims of the study were to characterize pelvic floor and urinary symptoms in women seeking treatment for uterine fibroids and to explore the association between uterine/fibroid size and pelvic floor symptoms.
Women seeking treatment for uterine fibroids at a single academic center were enrolled in this cross-sectional study. All participants underwent pelvic imaging and completed the Symptom Severity Subscale of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) and the Pelvic Floor Distress Inventory (PFDI-20).
One hundred ninety-five women with a mean age of 41 ± 6 years and body mass index of 29 ± 7 kg/m2 were included. In this cohort, 58% identified as Black and 38% had at least 1 vaginal delivery. Women attributed pelvic pain (68%), dyspareunia (37%), and urinary incontinence (31%) to their fibroids. The mean ± SD UFS-QOL score was 48.7 ± 25.4, and 63% of participants reported being at least "somewhat bothered" by tightness/pressure in pelvic area, 60% by frequent daytime urination, and 47% by nocturia. The mean PFDI-20 score was 45.5 ± 31.9. Women reported being at least "somewhat bothered" by heaviness/dullness in the pelvis (60%), frequent urination (56%), pelvic pain or discomfort (48%), and sensation of incomplete bladder emptying (43%). The PFDI-20 and UFS-QOL scores were not correlated with uterine volume (r = 0.12, P = 0.12, and r = 0.06, P = 0.44) or fibroid size (r = 0.09, P = 0.26, and r = 0.01, P = 0.92).
Women presenting for evaluation and treatment of fibroids report high rates of pelvic floor symptoms, particularly urinary frequency and pelvic pressure. However, uterine size and fibroid size are not associated with pelvic floor symptom bother.
本研究旨在描述寻求治疗子宫肌瘤女性的盆底和尿失禁症状，并探讨子宫/肌瘤大小与盆底症状之间的关系。
本横断面研究纳入了在单一学术中心寻求治疗子宫肌瘤的女性。所有参与者均接受了盆腔影像学检查，并完成了子宫肌瘤症状和健康相关生活质量问卷（UFS-QOL）的症状严重程度亚量表和盆底窘迫量表（PFDI-20）。
本研究共纳入了 195 名年龄 41 ± 6 岁、体重指数 29 ± 7kg/m2 的女性。在本队列中，58%的女性为黑人，38%至少有 1 次阴道分娩史。女性将盆腔疼痛（68%）、性交困难（37%）和尿失禁（31%）归因于肌瘤。UFS-QOL 评分的平均值±标准差为 48.7 ± 25.4，63%的参与者表示至少因盆腔区域的紧绷/压迫感而感到“有些困扰”，60%的参与者表示因白天尿频而感到“有些困扰”，47%的参与者因夜尿症而感到“有些困扰”。PFDI-20 评分的平均值±标准差为 45.5 ± 31.9。女性表示至少因骨盆沉重/钝痛（60%）、频繁排尿（56%）、盆腔疼痛或不适（48%）和膀胱排空不完全感（43%）而感到“有些困扰”。PFDI-20 和 UFS-QOL 评分与子宫体积（r = 0.12，P = 0.12，r = 0.06，P = 0.44）或肌瘤大小（r = 0.09，P = 0.26，r = 0.01，P = 0.92）均无相关性。
就诊评估和治疗子宫肌瘤的女性报告了较高的盆底症状发生率，尤其是尿频和盆腔压迫感。然而，子宫大小和肌瘤大小与盆底症状困扰无关。
